Technical Information Report

AAMI TIR35:
2016
Sterilization of health care products—
Radiation sterilization—
Product adoption and alternative sampling plans for verification dose experiments and sterilization dose audits

This is a preview edition of an AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

For a complete copy of this AAMI document, contact AAMI at +1-877-249-8226 or visit www.aami.org.
Sterilization of health care products—
Radiation sterilization—
Product adoption and alternative sampling plans for verification dose experiments and sterilization dose audits

Abstract:
Describes approaches to the selection and auditing of a sterilization dose that may reduce the number of product items required while maintaining assurance of attaining the desired sterility assurance level (SAL). This approach addresses sampling plans for verification dose experiments and sterilization dose audits. In addition the approaches to adopting a product into an established product family are defined.

Keywords: sterility, bioburden, radiation, health care products, dose, audits, product adoption, design verification, procedures
AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

Published by

Association for the Advancement of Medical Instrumentation
4301 N. Fairfax Drive, Suite 301,
Arlington, VA 22203-1633

© 2016 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of $100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI at 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633. Phone: (703) 525-4890

Printed in the United States of America

ISBN 1-57020-618-X
Contents

Glossary of equivalent standards .................................................................................................................... iv
Committee representation ................................................................................................................................ v
Introduction ................................................................................................................................................... viii
1 Scope ........................................................................................................................................................1
2 Normative references ................................................................................................................................1
3 Terms and definitions ................................................................................................................................1
4 Sample sizes for the verification dose experiment and dose establishment or dose audit. ......................2
  4.1 General ..........................................................................................................................................2
  4.2 Selection and testing of product .....................................................................................................3
  4.3 Procedures for verification dose experiments and sterilization dose audits ...................................3
    4.3.1 General ............................................................................................................................3
    4.3.2 Method 1: Alternative sampling plan for the verification dose experiment ..........................3
5 Evaluation and Methods for Product Adoption ........................................................................................ 19
  5.1 Evaluation of Candidate Product for Product Adoption ................................................................ 19
  5.2 Methods of Product Adoption ....................................................................................................... 20
  5.3 Designation of the Candidate Product as the Product Family Representative ............................. 21
6 Maintenance of Product Families ............................................................................................................ 21
Annex A (informative) Sample sizes for implementation of sampling plans and sampling scheme ............23
Annex B (informative) Radiation product adoption assessment flowchart ...................................................... 24
Bibliography ................................................................................................................................................... 26

Tables
1 Method 1: Alternative sampling plan for the verification dose experiment ..............................................5
2 Alternative sampling plan 1 for the sterilization dose audit (Methods 1 or 2) ............................................8
3 Alternative sampling plan 2 for the sterilization dose audit (Methods 1 or 2) ........................................11
4 Alternative sampling plan 3 for the sterilization dose audit (Methods 1 or 2) ........................................13
5 Alternative sampling scheme for Method 1: Sampling plan for the verification dose experiment (tightened inspection level) ..........................................................10
6 Alternative sampling scheme for Method 1: Sampling plan for the sterilization dose audit (reduced inspection level) ..........................................................19
A.1 Sample sizes for implementation of sampling plans and sampling scheme .....................................23
Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

www.aami.org/standards/glossary.pdf
Committee representation

Association for the Advancement of Medical Instrumentation

Radiation Sterilization Working Group

This technical information report was developed and balloted by the AAMI Radiation Sterilization Working Group under the auspices of the AAMI Sterilization Standards Committee. Approval of this technical information report does not necessarily imply that all working group members voted for its approval.

At the time this document was published, the AAMI Sterilization Standards Committee had the following members:

Cochair: Mike Scholla, Dupont Protection Technologies

Members:
- Richard Bancroft, Steris Corporation
- Trabue Bryans, BryKor LLC
- Nancy Chobin, St Barnabas Healthcare System
- Phil Cogdill, Medtronic Inc Campus
- Ramona Conner, Association of Perioperative Registered Nurses
- Jackie Daley, Sinai Hospital of Baltimore
- Kim Darnell, CR Bard
- Gordon Ely, MiMedx Group
- Lisa Foster, Adiuvo Quality Sterilization Consulting
- Joel Gorski, NAMS
- Joyce Hansen, Johnson & Johnson
- Doug Harbrecht, Sterility Assurance LLC
- Deborah Havlik, Hospira Worldwide Inc
- Sue Klacik, IAHCSMM
- Byron Lambert, Abbott Laboratories
- Colleen Landers, Timmins & District Hospital
- Michelle Luebke, Baxter Healthcare Corporation
- Jeff Martin, Alcon Laboratories Inc
- Patrick McCormick, Bausch & Lomb Inc
- Janet Prust, 3M Healthcare
- Nancy Rakiewicz, IUVO BioScience
- Andrew Sharavara, Propper Manufacturing Co Inc
- Mark Smith, Gelina, USA
- Joan Spear, B Braun of America Inc
- Stacy Wiehle, Boston Scientific Corporation
- Sid Wiggs
- Martell Winters, Nelson Laboratories Inc
- Bill Young, Sterigenics International

Alternates:
- Suzanne Butler, Boston Scientific Corporation
- Aaron Dement, Sterigenics International
- Dave Dion, Cardinal Health (MP&S)
- Ken Eddington, NAMS
- Diane Faiyre-Swiat, Cardinal Health (MP&S)
- Danny Hutson, Becton Dickinson & Company
- Natalie Lind, IAHC
- Jeffrey Marx, Steris Corporation
- Mary Mayo, CR Bard
- Gerry McDonnell, Johnson & Johnson
- David McGoldrick, Abbott Laboratories
- Jerry Nelson, Nelson Laboratories Inc
- Patrick Polito, IUVO BioScience
- Karen Polkinghorne, Dupont Protection Technologies
- Mike Sadowski, Baxter Healthcare Corporation
- Mike Schoene, Bausch & Lomb Inc
- Craig Wallace, 3M Healthcare
At the time this document was published, the AAMI Radiation Sterilization Working Group had the following members:

**Cochairs:**
- Emily Craven, Nordion Inc
- Pat Weixel, FDA/CDRH

**Members:**
- Ed Arscott, NAMSA
- Simon Bogdansky, Allo Source
- Curt Bogue, Cook Inc
- Anne Booth, Booth Scientific Inc
- Riley Brown, St Jude Medical Inc
- Trabue Bryans, BryKor LLC
- Harry Bushar
- David Cardin, Zimmer Inc
- Sarah Chamberlain, Accuratus Labs Services
- Denise Cleghorn, Boston Scientific Corporation
- Gary Cranston, Consulting & Technical Services/PCS
- Greg Crego, IUVO BioScience
- Elaine Daniell, CR Bard
- Douglas Davie, Sterilization Validation Services
- Jeffrey DelGaudio, Medtronic Inc Campus
- Darci Diage, Direct Flow Medical Inc
- Dave Dion, Cardinal Health (MP&S)
- Francesco Famosi, Arthrex Inc
- William FitzGerald, FitzGerald & Associates Ltd
- Lisa Foster, Adjuvo Quality & Sterilization Consulting
- Matthew Freeman, Terumo BCT
- Shelley Green, WuXi AppTec Inc
- Joyce Hansen, Johnson & Johnson
- Doug Harbrecht, Sterility Assurance LLC
- Deborah Havlik, Hospira Worldwide Inc
- Donna Homer, Abbott Laboratories
- Betty Howard, Steris Corporation
- Carolyn Kinsley, Lexamed Ltd
- Jeff Martin, Alcon Laboratories Inc
- Patrick McCormick, Bausch & Lomb Inc
- Nicole McLees, 3M Healthcare
- Rusty Mills, GE Healthcare
- Larry Nichols, Nutek Corporation
- Gerry O’Dell, Gerry O’Dell Consulting
- Kevin O’Hara, Sterigenics International
- Dave Parente, Ecolab
- Kimberly Patton, Boston Dickinson & Company
- Michelle Peterson, Stryker Instruments Division
- Rudy Pina, Dynatec Scientific Labs Inc
- Keith Reiner, Terumo Americas Corporate
- Jody Rupert, WL Gore & Associates Inc
- Manny Saavedra, Halyard Health
- Liza Salerno, Accuratus Labs Services
- Harry Shaffer, Sterilization Consulting Services
- Michael Sprague, Ethide Laboratories Inc
- Sopheak Srun, Quality Tech Services Inc
- Fenil Sutaria, Medline Industries Inc
- Jill Warren, WuXi AppTec Inc
- Bud Weisman, Fresenius Medical Care
- Beverly Whitaker, Indigo Consulting Group LLC
- Martell Winters, Nelson Laboratories Inc

**Alternates:**
- MarJean Boyter, Fresenius Medical Care -
- Carolyn Braithwaite-Nelson, Spectranetics Corporation
- Rachel Brewer, IUVO BioScience
- Claudia Camp, Stryker Instruments Division
NOTE—Participation by federal agency representatives in the development of this technical information report does not constitute endorsement by the federal government or any of its agencies. This is a preview edition of an AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

For a complete copy of this AAMI document, contact AAMI at +1-877-249-8226 or visit www.aami.org.
Introduction

This technical information report (TIR) is intended to be used in conjunction with the ANSI/AAMI/ISO 11137 series. One of the activities encompassed within this series is the selection and routine auditing of the sterilization dose to be applied to health care products, and, in relation, the number of product items to be used to assure the sterility assurance level (SAL) is attained. A primary manufacturer might wish to reduce this number.

The guidance contained within this TIR provides strategies by which the primary manufacturer may reduce the total number of product items to be tested for establishing and maintaining the sterilization dose with alternative sampling plans. The approach to alternative sampling plans given in this TIR employs alternative sampling plans that are statistically equivalent to the sample size of 100 product items as described in Methods 1 and 2 of ANSI/AAMI/ISO 11137-2, even though a different number of products is tested. However, if there is a dose audit failure when using this approach, there is no provision for the augmentation of the sterilization dose. In this situation, the dose must be re-established or another validation method utilized.

The TIR also provides guidance by which the primary manufacturer may adopt new products or redesigned products into an established product family with a technical evaluation. Based upon the technical evaluation the method to be used to adopt the product into the family can be determined.


NOTE—This technical information report is not a standard and the material contained herein is not normative in nature. The committee has in a few places used the term "shall" based on their knowledge of requirements contained in relevant standards and/or regulatory requirements.
Sterilization of health care products—Radiation sterilization—Product adoption and alternative sampling plans for verification dose experiments and sterilization dose audits.

1 Scope

This TIR describes approaches to the selection and auditing of a sterilization dose that may reduce the number of product items required while maintaining assurance of attaining the desired sterility assurance level (SAL). This approach addresses sampling plans for verification dose experiments and sterilization dose audits. Additionally, guidance for adopting a product into an existing product family and maintenance of product families is provided.

2 Normative references


3 Terms and definitions

For the purposes of this TIR, the following terms and definitions apply:

3.1 augmentation

Action taken to increase the sterilization dose based upon the results obtained from a sterilization dose audit.

3.2 bioburden

Population of viable microorganisms on or in product and/or a sterile barrier system.

3.3 candidate product

The product being examined for adoption into an existing product family.

3.4 false positive

Test result interpreted as growth arising from the product, or portions thereof, tested when either growth resulted from extraneous microbial contamination or turbidity occurred from interaction between the product, or portions thereof, and the test medium.

3.5 health care product

Medical device(s), including in vitro diagnostic medical device(s), or medical product(s), including biopharmaceuticals.